Fig. 6

Structure and validation of selected treatment outcome-prognostic transcripts. a–c Structure of GENCODE-annotated and de novo-assembled SOBP, WDR76 and BRIP1 transcripts. Location of PCR primers used is represented by pink or green arrowheads for different pairs. RNA-seq read coverage in HSCs isolated prior to 5-AZA treatment from representative samples of MDS (GEO531A16, GEO531A3, GEO531A5) and CMML (GEO531A6, GEO531A32, GEO531A7) patients who subsequently responded (complete response) or failed to respond (failure) to 6 cycles of treatment in our study and in SRP067631. Patient GEO531A32 had a mutation in the spliceosome complex gene U2AF1. d Expression of qRT-PCR products amplified by primer pairs shown in a–c and Additional file 2: Figure S8 normalised to HPRT expression, in MDS and CMML patients, according to their response to 5-AZA treatment. The cumulative expression is the sum of normalised expression